C

China Medical System Holdings Ltd
SWB:2M7C

Watchlist Manager
China Medical System Holdings Ltd
SWB:2M7C
Watchlist
Price: 0.885 EUR -3.8% Market Closed
Market Cap: 3.6B EUR
Have any thoughts about
China Medical System Holdings Ltd?
Write Note

China Medical System Holdings Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

China Medical System Holdings Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
C
China Medical System Holdings Ltd
SWB:2M7C
Income from Continuing Operations
¥1.4B
CAGR 3-Years
-22%
CAGR 5-Years
-8%
CAGR 10-Years
7%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Income from Continuing Operations
HK$2.4B
CAGR 3-Years
2%
CAGR 5-Years
21%
CAGR 10-Years
34%
U
United Laboratories International Holdings Ltd
HKEX:3933
Income from Continuing Operations
¥2.9B
CAGR 3-Years
37%
CAGR 5-Years
27%
CAGR 10-Years
18%
Sino Biopharmaceutical Ltd
HKEX:1177
Income from Continuing Operations
¥4.9B
CAGR 3-Years
-26%
CAGR 5-Years
-15%
CAGR 10-Years
12%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Income from Continuing Operations
HK$13.3B
CAGR 3-Years
32%
CAGR 5-Years
10%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Income from Continuing Operations
-$42.2m
CAGR 3-Years
37%
CAGR 5-Years
13%
CAGR 10-Years
N/A
No Stocks Found

China Medical System Holdings Ltd
Glance View

Market Cap
3.6B EUR
Industry
Pharmaceuticals

China Medical System Holdings Ltd. engages in the production, marketing, promotion, and sale of drugs. The company employs 5,622 full-time employees The company went IPO on 2010-09-28. The firm's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The firm distributes its products within domestic market and to overseas markets.

2M7C Intrinsic Value
1.301 EUR
Undervaluation 32%
Intrinsic Value
Price
C

See Also

What is China Medical System Holdings Ltd's Income from Continuing Operations?
Income from Continuing Operations
1.4B CNY

Based on the financial report for Jun 30, 2024, China Medical System Holdings Ltd's Income from Continuing Operations amounts to 1.4B CNY.

What is China Medical System Holdings Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
7%

Over the last year, the Income from Continuing Operations growth was -60%. The average annual Income from Continuing Operations growth rates for China Medical System Holdings Ltd have been -22% over the past three years , -8% over the past five years , and 7% over the past ten years .

Back to Top